Brian Barnett

Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.

2 papers in the library · 38 citations · publishing 2023-2024

Papers

Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open June 3, 2024 Manish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan et al. 29 citations

In people with treatment-resistant depression who do not have psychosis, intravenous ketamine works as well as electroconvulsive therapy (ECT) overall. Among outpatients with moderately severe or severe depression, ketamine produced greater improvement in depressive symptoms than ECT. In contrast, inpatients with very severe depression improved more with ECT early in treatment, though by the end of the three-week course both treatments were similarly effective. Higher premorbid intelligence and a diagnosis of posttraumatic stress disorder were linked to greater improvement with ECT, but not with ketamine. These findings may help patients and clinicians decide between the two treatments.

DOI: 10.1001/jamanetworkopen.2024.17786 Full text Depression treatment Ketamine therapy Electroconvulsive therapy Mental health interventions +1

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.

Psychedelic medicine (New Rochelle, N.Y.) September 1, 2023 Zachary Herrmann, Adam W Levin, Steven P Cole et al. 9 citations

Among 228 healthcare providers who treat psychiatric disorders with medications and reported at least one lifetime psychedelic use, retrospective measures showed improvements in depression, anxiety, and well-being after psychedelic exposure. Suicidality decreased and resilience increased. A factor analysis indicated that a cluster of mystical, interpersonal, and personal experiences predicted these improvements. The preferred psychedelic agent did not affect outcomes, and frequency of use was not associated with outcomes, though effect sizes varied. Harm was reported by 13.2% (n = 30), consistent with general population rates. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often, while marijuana use most often worsened or did not change.

DOI: 10.1089/psymed.2023.0030 Full text Anxiety Depression Psilocybin Prescriber +5